Mar 06, 2018
By Andy Johnson
An Osaka-based pharmaceutical company has been cleared to manufacture and market its new drug Xofluza, which could rival Tamiflu, made by Swiss drug maker Roche.
Antivirals like Tamiflu are taken in multiple doses over several days and stop the flu virus by binding to a coating on the virus’ surface to inhibit its ability to escape an infected cell.
Xofluza requires a single pill and suppresses virus replication by targeting an enzyme.